Search Results for

BGB-11417-301

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia

Continue Reading »

---

CABL001J12302

A Phase IIIb, Multi-center, Open-label, Randomized Study of Tolerability and Efficacy of Oral Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.

Continue Reading »

---

EA9213 (JIT)

A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute
Lymphoblastic Leukemia (T-ALL)

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Anal  (1) Bladder/Urinary Tract Cancer  (5)    Adjuvant  (1)    Metastatic  (2) Brain  (9)    Glioblastoma Multiforme (GBM)  (1)    Other Brain Tumors  (3) Breast  (14)    Breast Cancer Adjuvant  (1)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (20) Carcinoid Tumors  (2) Colorectal Cancer  (6)    Metastatic  (1)    Rectal Neoadjuvant  (1) Esophageal Cancer  (4) Gastric Cancer  (3) Head/Neck Cancer  (9) Leukemia  (3)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (1) Lung Cancer  (18)    Non-Small Cell Lung Cancer  (14)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (2)       Adjuvant Treatment for Resected NSCLC  (2)    Small Cell Lung Cancer  (3)       Extensive Stage SCLC  (1) MATCH Trial  (3) Melanoma  (2) Merkel Cell Carcinoma  (1) Misc. Gynecology  (4) Multiple Myeloma  (3) Ovarian  (2) Pancreatic  (8)    Metastatic Disease  (1) Prostate  (9) Renal Cell/Kidney Cancer  (3)    Locally Advanced/Metastatic  (1) Sarcoma  (1)